Ucb SA
XBRU:UCB
Ucb SA
Operating Expenses
Ucb SA
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ucb SA
XBRU:UCB
|
Operating Expenses
-€3.6B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Financiere de Tubize SA
XBRU:TUB
|
Operating Expenses
-€1k
|
CAGR 3-Years
93%
|
CAGR 5-Years
75%
|
CAGR 10-Years
47%
|
|
|
Hyloris Pharmaceuticals SA
XBRU:HYL
|
Operating Expenses
-€17.8m
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
Ucb SA
Glance View
UCB SA, a Belgian multinational biopharmaceutical company, stands at the forefront of innovation in the medical field, committed to creating value by discovering new ways to treat severe diseases. Founded in 1928, UCB has transformed over the decades from its initial focus in chemicals to pioneering developments in advanced therapeutics targeting central nervous system disorders and immunology. Anchored by a robust research pipeline and a keen focus on rare diseases and specialty care, UCB has established a strong presence globally, reflecting its strategic pivot toward patient-centric approaches. With primary research facilities stationed in Braine-l'Alleud, Belgium, and Slough, UK, the company's scientific endeavors are bolstered by collaborations with research institutions worldwide, fostering an environment ripe for breakthrough discoveries. Financially, UCB's revenue streams are predominantly derived from its established portfolio of blockbuster drugs, such as Cimzia, Vimpat, and Keppra, which serve as critical lifelines for patients dealing with autoimmune diseases, epilepsy, and other chronic conditions. The company thrives on a dynamic business model that combines in-house scientific research with strategic partnerships and acquisitions to enhance its competitive edge. This synergy not only facilitates sustained growth in its core markets but also drives expansion into emerging ones, underscoring its global reach. By reinvesting substantial portions of its earnings into research and development, UCB ensures a steady pipeline of new products, thereby maintaining its stature in the highly competitive biopharmaceutical landscape. Through such strategic maneuvers, UCB aligns its operations with the overarching goal of delivering transformative therapies that improve the quality of life for patients around the world.
See Also
What is Ucb SA's Operating Expenses?
Operating Expenses
-3.6B
EUR
Based on the financial report for Dec 31, 2024, Ucb SA's Operating Expenses amounts to -3.6B EUR.
What is Ucb SA's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-7%
Over the last year, the Operating Expenses growth was -17%. The average annual Operating Expenses growth rates for Ucb SA have been -6% over the past three years , -7% over the past five years .
You don't have any saved screeners yet